These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21122630)

  • 1. Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence.
    Davidson MH
    J Clin Lipidol; 2010; 4(1):72-3; discussion 74. PubMed ID: 21122630
    [No Abstract]   [Full Text] [Related]  

  • 2. Point: Low-density lipoprotein cholesterol goals in patients with diabetes are not adequately based on evidence.
    Gosmanov AR
    J Clin Lipidol; 2010; 4(1):69-71; discussion 74. PubMed ID: 21122629
    [No Abstract]   [Full Text] [Related]  

  • 3. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Guideline for management of lipid metabolism].
    Ishibashi S
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():675-8. PubMed ID: 12387068
    [No Abstract]   [Full Text] [Related]  

  • 6. [Considerable LDL lowering is advantageous].
    MMW Fortschr Med; 2005 Sep; 147(35-36):9. PubMed ID: 16180563
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol goals established for patients with diabetes and metabolic syndrome.
    Haffner SM
    Am J Manag Care; 2002 Jan; Suppl():6-7. PubMed ID: 11833456
    [No Abstract]   [Full Text] [Related]  

  • 9. Government cholesterol recommendations questioned.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Oct; 15(20):9-10, 12. PubMed ID: 15505935
    [No Abstract]   [Full Text] [Related]  

  • 10. [To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too].
    MMW Fortschr Med; 2005 Aug; 147(33-34):51. PubMed ID: 16138641
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins and diabetes.
    Feeman WE
    Lancet; 2008 May; 371(9626):1752; author reply 1752. PubMed ID: 18502296
    [No Abstract]   [Full Text] [Related]  

  • 13. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
    Polis AB; Abate N; Catapano AL; Ballantyne CM; Davidson MH; Smugar SS; Tershakovec AM
    Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk].
    Olsson AG
    Lakartidningen; 2011 Jun 1-14; 108(22-23):1240-3. PubMed ID: 21786498
    [No Abstract]   [Full Text] [Related]  

  • 16. Rising to the challenge of treating high-risk patients.
    Guthrie RM
    Am J Manag Care; 2006 Oct; 12(11 Suppl):S318-24. PubMed ID: 17042674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose statin therapy: benefits and safety in aggressive lipid lowering.
    Toth PP; Davidson MH
    J Fam Pract; 2008 May; 57(5 Suppl High-Dose):S29-36. PubMed ID: 18662521
    [No Abstract]   [Full Text] [Related]  

  • 18. Are we lowering LDL cholesterol sufficiently?
    Barter P; Rye KA
    Nat Clin Pract Cardiovasc Med; 2006 Jun; 3(6):290-1. PubMed ID: 16728988
    [No Abstract]   [Full Text] [Related]  

  • 19. [The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention].
    Olsson AG
    Lakartidningen; 2011 Nov 23-29; 108(47):2442-3. PubMed ID: 22468387
    [No Abstract]   [Full Text] [Related]  

  • 20. Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy.
    Rapezzi C; Biagini E; Bellis P; Cafiero M; Velussi M; Ceriello A; Cooke RM; Schweiger C;
    J Cardiovasc Med (Hagerstown); 2008 Sep; 9(9):878-87. PubMed ID: 18695423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.